EUVIMEDEUVIMED entdecken
Crossref

Long-term Cancer Control Outcomes After Robot-assisted Radical Prostatectomy in Pathologically Non–organ-confined High-risk Prostate Cancer: 20-year Report from a Single Tertiary Referral Center

Alessandro Bertini, Alex Stephens, Alessio Finocchiaro, Silvia Viganò, Arjun Dinesh, Elnaz Guivatchian, Antonio Perri, Giovanni Lughezzani, Nicolò Buffi, Ettore Di Trapani, Vincenzo Ficarra, Alberto Briganti und 6 weitere

European Urology Focus · 2025

DOI: 10.1016/j.euf.2025.07.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2025. Verfasst von Alessandro Bertini und 17 weiteren Autor:innen. Beteiligte Einrichtung: VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, MI, USA; Division of Oncology, Unit of Urology, IRCCS …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Robotic Surgical Procedures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Vattikuti Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Exhaustive evidence on the long-term efficacy of robot-assisted laparoscopic prostatectomy (RALP) in non-organ-confined high-risk prostate cancer (PC) is still lacking. Our aim was to evaluate long-term oncological outcomes in this subset of patients treated with RALP at a single referral center. METHODS: We included 803 patients with pathologically non-organ-confined high-risk PC (≥pT3a and/or pN1) at RALP between 2001 and 2022 at Henry Ford Hospital (Detroit, MI, USA). All patient underwent RALP using the Vattikuti Institute technique, with or without extended pelvic lymph node dissection (external iliac, obturator, and internal iliac nodes). The Kaplan-Meier method was used to estimate overall survival (OS) and additional treatment-free survival. The probability of PC-specific survival (PCSS) was estimated via the competing-risks method. Competing-risk and Cox regression analyses were used to identify potential predictors of PC-specific mortality (PCSM), any-cause mortality (ACM), and additional treatment. KEY FINDINGS AND LIMITATIONS: We included 803 patients, of whom 415 (51.5%) had pT3a, 385 (47.9%) had ≥pT3b, 323 (40%) had pN1, and 670 (84%) had grade group 4-5 PC. Of the 635 patients with status information regarding additional treatment, 416 received further therapy after surgery. Specifically, 46, 110, and 260 underwent RT only, HT only, or RT + HT, respectively. Median follow-up was 72 mo (interquartile range 28-120). The 20-yr survival rates were 72.7% (95% confidence interval [CI] 56.8-86,5%) for PCSS and 45.2% (95% CI 29.1-60.1%) for OS. The rates of survival free from additional treatment were 31.3% (95% CI 26.1-36.5%) at 10 yr and 20.3% (95% CI 14.9-26.4%) at 15 yr. Multivariable regression revealed pT3b-4 stage as an independent predictor of PCSM (hazard ratio [HR] 2.50; p = 0.008), ACM (HR 1.84; p = 0.006), and additional treatment (HR 1.69; p < 0.001). CONCLUSIONS AND CLINICAL IMPLICATIONS: For patients with non-organ-confined high-risk PC, RALP achieves long-term oncological control. This study provides the longest follow-up after RALP as the primary local treatment for patients with truly aggressive PC forms and offers valuable insights for patient counseling on long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatectomyRobotic Surgical ProceduresHumansMaleMiddle AgedTertiary Care CentersAgedTreatment OutcomeRetrospective StudiesLymph Node Excision

Stichwörter der Autor:innen

Locally advancedLong-term oncological outcomesProstate cancerRobot-assisted radical prostatectomy

Autor:innen und Institutionen

  • VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, MI, USA; Division of Oncology, Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Ita…
  • Public Health Sciences, Henry Ford Health System, Detroit, MI, USA.
  • VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, MI, USA; Department of Urology, IRCCS Humanitas Research Hospital, Humanitas University, Milan, Italy.
  • VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, MI, USA; Department of Clinical and Experimental Medicine, Department of Oncology, Urologic section, AOU G. Martino, Univers…
  • VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, MI, USA.
  • Wayne State University, School of Medicine, Detroit, MI, USA.

Förderung

  • Vattikuti Foundation

Zitieren

APA

Bertini, A., Stephens, A., Finocchiaro, A., Viganò, S., Dinesh, A., Guivatchian, E., Perri, A., Lughezzani, G., Buffi, N., Di Trapani, E., Ficarra, V., Briganti, A., Salonia, A., Montorsi, F., Sood, A., Menon, M., Rogers, C., & Abdollah, F. (2025). Long-term Cancer Control Outcomes After Robot-assisted Radical Prostatectomy in Pathologically Non–organ-confined High-risk Prostate Cancer: 20-year Report from a Single Tertiary Referral Center. European Urology Focus. https://doi.org/10.1016/j.euf.2025.07.007

Vancouver

Bertini A, Stephens A, Finocchiaro A, Viganò S, Dinesh A, Guivatchian E, et al. Long-term Cancer Control Outcomes After Robot-assisted Radical Prostatectomy in Pathologically Non–organ-confined High-risk Prostate Cancer: 20-year Report from a Single Tertiary Referral Center. European Urology Focus. 2025. doi:10.1016/j.euf.2025.07.007

BibTeX
@article{Bertini2025,
  author = {Bertini, Alessandro and Stephens, Alex and Finocchiaro, Alessio and Viganò, Silvia and Dinesh, Arjun and Guivatchian, Elnaz and Perri, Antonio and Lughezzani, Giovanni and Buffi, Nicolò and Di Trapani, Ettore and Ficarra, Vincenzo and Briganti, Alberto and Salonia, Andrea and Montorsi, Francesco and Sood, Akshay and Menon, Mani and Rogers, Craig and Abdollah, Firas},
  title = {Long-term Cancer Control Outcomes After Robot-assisted Radical Prostatectomy in Pathologically Non–organ-confined High-risk Prostate Cancer: 20-year Report from a Single Tertiary Referral Center},
  journal = {European Urology Focus},
  year = {2025},
  doi = {10.1016/j.euf.2025.07.007}
}
Kostenlos starten →